Tandem Diabetes Care (TNDM) EPS (Basic) Growth (5y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Tandem Diabetes Care | 1.31 Bn | 739.55 Mn | 136.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.26% |
| Dec 31, 2025 | -15.29% |
| Sep 30, 2025 | -15.63% |
| Jun 30, 2025 | -11.63% |
| Mar 31, 2025 | -51.11% |
| Dec 31, 2024 | -24.21% |
| Sep 30, 2024 | -47.58% |
| Jun 30, 2024 | -73.38% |
| Mar 31, 2024 | -10.20% |
| Dec 31, 2023 | -57.42% |
| Sep 30, 2023 | 3.83% |
| Jun 30, 2023 | 14.01% |
| Mar 31, 2023 | -1.08% |
| Dec 31, 2022 | 27.29% |
| Sep 30, 2022 | 24.46% |
| Jun 30, 2022 | 44.48% |
| Mar 31, 2022 | 50.13% |
| Dec 31, 2021 | 15.27% |
| Sep 30, 2021 | 14.98% |
| Jun 30, 2021 | 14.98% |
| Mar 31, 2021 | 58.87% |
| Dec 31, 2020 | 21.75% |
| Sep 30, 2020 | 25.42% |
| Jun 30, 2020 | 7.09% |
| Mar 31, 2020 | 21.34% |
| Dec 31, 2019 | 15.45% |
| Sep 30, 2019 | 43.26% |
| Jun 30, 2019 | 48.52% |
| Mar 31, 2019 | 16.06% |
| Dec 31, 2018 | 15.19% |
| Sep 30, 2018 | 60.05% |
| Jun 30, 2018 | 56.19% |
| Mar 31, 2018 | 49.20% |